Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Sends Sutent sNDA For Pancreatic Cancer To ODAC

This article was originally published in The Pink Sheet Daily

Executive Summary

Oncologic Drugs Advisory Committee's April 12 review may have been spurred by any number of issues in the Phase III trial, including its early termination, reliability of progression-free survival assessments and failure to show quality-of-life improvements.

You may also be interested in...



Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer

FDA is asking its Oncologic Drugs Advisory Committee whether sunitinib's risk/benefit profile in pancreatic neuroendocrine tumors is favorable given that early termination of the Phase III trial created uncertainty about the magnitude of its progression-free survival benefit.

Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer

FDA is asking its Oncologic Drugs Advisory Committee whether sunitinib's risk/benefit profile in pancreatic neuroendocrine tumors is favorable given that early termination of the Phase III trial created uncertainty about the magnitude of its progression-free survival benefit.

FDA's Avastin Decision Puts Pressure On Progression-Free Survival Endpoints

As FDA started to reconsider the approval of Roche/Genentech's Avastin for metastatic breast cancer, many were concerned about the decision's potential implications for other applications using progression-free survival as an endpoint.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel